ACTICOR BIOTECH, a clinical-stage pharmaceutical company, reports its voting rights and shares as of May 31, 2024. The company focuses on developing glenzocimab, a drug for treating cardiovascular emergencies, particularly ischemic stroke.
Glenzocimab has shown promising results in Phase 1b/2a (ACTIMIS) and Phase 2/3 (ACTISAVE) clinical trials. ACTIMIS demonstrated glenzocimab’s safety profile and reduced mortality and intracerebral hemorrhage in stroke patients. AI brain imaging analysis confirmed these results, indicating a reduction in lesions.
Despite initial negative results on the primary endpoint (disability or death), ACTISAVE data presented at ESOC 2024 showed trends in returning to normal life, especially in patients with complete recanalization after mechanical thrombectomy.
ACTICOR BIOTECH is supported by European and international investors and has been listed on Euronext Growth Paris since November 2021. The company is actively involved in ongoing clinical trials and continues to evaluate glenzocimab’s potential in treating cardiovascular emergencies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
